Skip to main content

Daclatasvir Dosage

Applies to the following strengths: 90 mg; 30 mg; 60 mg

Usual Adult Dose for Chronic Hepatitis C

60 mg orally once a day

Recommended Regimen and Duration of Therapy:
Genotype 1:


Genotype 3:

Comments:

Use: With sofosbuvir (with or without ribavirin), for the treatment chronic HCV genotype 1 or 3 infection

Renal Dose Adjustments

No adjustment recommended.

Comments:

Liver Dose Adjustments

Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): No adjustment recommended.

Comments:

Dose Adjustments

Coadministration with strong CYP450 3A inhibitors and certain HIV antiviral agents: 30 mg orally once a day
Coadministration with moderate CYP450 3A inducers and nevirapine: 90 mg orally once a day
Coadministration with strong CYP450 3A inducers: Contraindicated

The dose of this drug should not be reduced for side effects.

If sofosbuvir is permanently discontinued, this drug should also be discontinued.

Precautions

US BOXED WARNING:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:

Other Comments

Administration advice:


General:

Patient advice:

Frequently asked questions

More about daclatasvir

Patient resources

Other brands

Daklinza

Professional resources

Other brands

Daklinza

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.